

Yasuhiro Funahashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6844927/publications.pdf>

Version: 2024-02-01

23
papers

3,189
citations

394286

19
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

3455
citing authors

#	ARTICLE	IF	CITATIONS
1	E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. <i>International Journal of Cancer</i> , 2008, 122, 664-671.	2.3	443
2	Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase. <i>Clinical Cancer Research</i> , 2008, 14, 5459-5465.	3.2	431
3	Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models. <i>Journal of Thyroid Research</i> , 2014, 2014, 1-13.	0.5	350
4	Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. <i>Vascular Cell</i> , 2014, 6, 18.	0.2	349
5	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. <i>PLoS ONE</i> , 2019, 14, e0212513.	1.1	294
6	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1â€6 hepatocellular carcinoma model. <i>Cancer Science</i> , 2018, 109, 3993-4002.	1.7	215
7	Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. <i>Cancer Science</i> , 2014, 105, 1334-1342.	1.7	206
8	Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 89-94.	1.3	194
9	Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. <i>Cancer Medicine</i> , 2018, 7, 2641-2653.	1.3	163
10	Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. <i>Cancer Research</i> , 2002, 62, 6116-23.	0.4	82
11	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	1.3	59
12	Inhibition of FGFR Reactivates IFNÎ³ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. <i>Cancer Research</i> , 2022, 82, 292-306.	0.4	58
13	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 575-582.	0.6	53
14	Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFRâ€MAPK cascades. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 1-7.	1.0	51
15	Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. <i>Cancer Science</i> , 2017, 108, 763-771.	1.7	50
16	The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. <i>Future Oncology</i> , 2021, 17, 637-648.	1.1	42
17	Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. <i>Clinical Cancer Research</i> , 2021, 27, 4848-4858.	3.2	39
18	Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy. <i>Scientific Reports</i> , 2020, 10, 2939.	1.6	33

#	ARTICLE	IF	CITATIONS
19	E7386, a Selective Inhibitor of the Interaction between β^2 -Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling. <i>Cancer Research</i> , 2021, 81, 1052-1062.	0.4	30
20	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
21	Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2019, 37, 185-198.	0.6	14
22	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
23	Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models. <i>Anticancer Research</i> , 2020, 40, 6699-6712.	0.5	2